Penn Medicine
Help | Search | Site Map | Contact   
faculty photo

Selina M. Luger, M.D.

Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician , Hospital of the University of Pennsylvania
Member , Abramson Cancer Center, University of Pennsylvania
Director, Outpatient Practice, Stem Cell Transplant & Hematological Malignancies, Hospital of the University of Pennsylvania
Director, Leukemia Program, Abramson Cancer Center, Perelman School of Medicine
Member, Electronic Medical Record Oversight Committee
Member, Sunrise Physician Advisory Board
Chair, Hematology-Oncology Epic Governance, Perelman School of Medicine, University of Pennsylvania
Member, Clinical Leadership Committee, Department of Medicine
Member, Epic Operations Committee, Hospital of the University of Pennsylvania
Medical Board, Member, Executive Committee, Hospital of the University of Pennsylvania
Member, Penn Chart Development Committee, Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-101
34th and Civic Center Blvd
Philadelphia, PA 19104
Office: 215-614-1847
Fax: 215-662-4064
Education:
A.B. (Biochemistry)
Harvard University, 1982.
M.D.CM (Medicine)
McGill University, 1987.
Post-Graduate Training
Intern, Internal Medicine , Presbyterian University Hospital, Pittsburgh, 1987-1988.
Resident, Internal Medicine , Presbyterian University Hospital, Pittsburgh, 1988-1990.
Fellowship, Hematology-Oncology , University of Pennsylvania, Philadelphia, 1990-1993.
Certifications
ABIM/Internal Medicine, 1990.
Royal College of Physicians & Surgeons of Canada, 1990.
ABIM/Medical Oncology, 1993.
ABIM/Hematology, 2006.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Leukemia, myelodysplastic syndrome, myeloproliferative disorders
MDS, AML, CML, ALL

Description of Clinical Expertise

hematologic malignancies, leukemia, AML, ALL, CML, myelodysplastic syndrome, MDS, myeloproliferative disorders, stem cell transplantation, bone marrow transplant

Selected Publications

Pasquini MC, Zhang MJ, Medeiros BC, Armand P, Hu ZH, Nishihori T, Aljurf MD, Akpek G, Cahn JY, Cairo MS, Cerny J, Copelan EA, Deol A, Freytes CO, Gale RP, Ganguly S, George B, Gupta V, Hale GA, Kamble RT, Klumpp TR, Lazarus HM, Luger SM, Liesveld JL, Litzow MR, Marks DI, Martino R, Norkin M, Olsson RF, Oran B, Pawarode A, Pulsipher MA, Ramanathan M, Reshef R, Saad AA, Saber W, Savani BN, Schouten HC, Ringdén O, Tallman MS, Uy GL, Wood WA Jr, Wirk B, Pérez WS, Batiwalla M, Weisdorf DJ: Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biol Blood Marrow Transplant. 22(2): 248-57, Feb 2016

Canaani J, Luger SM.: Revisiting maintenance therapy in acute myeloid leukemia with novel agents. Curr Opin Hematol. Mar 2016.

Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP, Lazarus HM, Levine RL, Litzow MR, Paietta EM, Patel JP, Racevskis J, Rowe JM, Tallman MS, Sun Z, Luger SM.: Benefit of high dose daunorubicin in AML induction extends across cytogenetic and molecular groups: updated analysis of E1900. Blood Jan 2016.

Kumar AJ, Vassilev P, Loren AW, Luger SM, Reshef R, Gill S, Smith J, Goldstein SC, Hexner E, Stadtmauer EA, Porter D, Frey NV.: Time to Unrelated Donor Leukocyte Infusion is Longer, but Incidence of GVHD and Overall Survival are Similar for Recipients of Unrelated DLI Compared to Matched Sibling DLI. Am J Hematol Jan 2016.

Lee EJ, Smith BD, Merrey JW, Lee AI, Podoltsev NA, Barbarotta L, Litzow MR, Prebet T, Luger SM, Gore S, Streiff MB, Zeidan AM: Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey. Clin Lymphoma Myeloma Leuk 15(12): 766-770, Dec 2015.

Zent CS, Wang XV, Ketterling RP, Hanson CA, Libby EN, Barrientos JC, Call TG, Chang JE, Liu JJ, Calvo AR, Lazarus HM, Rowe JM, Luger SM, Litzow MR, Tallman MS.: A Phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: A Trial of the ECOG-ACRIN Cancer Research Group (E1908). Am J Hematol Dec 2015.

Luskin MR, Ganetsky A, Landsburg DJ, Loren AW, Porter DL, Nasta SD, Svoboda J, Luger SM, Frey NV.: Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma. Br J Haematol Sep 2015.

Paul TM, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Nasta SD, Loren A, Frey N, Perl A, Cohen AD, Weiss BM, Stadtmauer EA, Vogl DT.: Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma. Clin Lymphoma Myeloma Leuk. 15(9): 536-40, Sep 2015.

Reshef R, Huffman AP, Gao A, Luskin MR, Frey NV, Gill SI, Hexner EO, Kambayashi T, Loren AW, Luger SM, Mangan JK, Nasta SD, Richman LP, Sell M, Stadtmauer EA, Vonderheide RH, Mick R, Porter DL.: High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. J Clin Oncol 33(21): 2392-8, Jul 2015.

DiPersio JF1, Erba HP2, Larson RA3, Luger SM4, Tallman MS5, Brill JM6, Vuagniaux G7, Rouits E7, Sorensen JM6, Zanna C7. : Oral Debio1143 (AT406), an Antagonist of Inhibitor of Apoptosis Proteins, Combined With Daunorubicin and Cytarabine in Patients With Poor-Risk Acute Myeloid Leukemia-Results of a Phase I Dose-Escalation Study. Clin Lymphoma Myeloma Leuk 15(7): 443-9, Mar 2015.

back to top
Last updated: 07/14/2016
The Trustees of the University of Pennsylvania
 
© The Trustees of the University of Pennsylvania. Site best viewed with Mozilla, NN, IE, or Safari.
SOM Home International Programs Penn Alumni Clinical Trials Centers and Institutes Departments Faculty Research Education Administration